![Senior or Adult patient looking at ipad - Medicare or Medicaid](https://amcp.org/sites/default/files/styles/card_fullsize/public/images/AMCP%20Seniors%20and%20Adults%20Medicare%20-%20ipad.jpg.webp?itok=PCGyb3FL)
View AMCP letter urging Congress to support 12-month continuous eligibility for adults in Medicaid and the Children’s Health Insurance Program (CHIP) by passing the Stabilize Medicaid and CHIP Coverage Act
On Aug. 6, AMCP responded to FDA’s draft guidance on considerations in demonstrating biosimilar interchangeability with a biologic reference product. The draft guidance, issued on June 17, describes considerations regarding switching studies which demonstrate interchangeability between biosimilars and their reference biologic products.
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.